NCT04943848 2026-03-17
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1 Recruiting
Clinical Trials
14 trialsNCT05264974 2026-01-21
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
University of Florida
Phase 1 Recruiting
NCT05378464 2026-01-08
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT03092453 2024-12-24
Dendritic Cell Vaccination in Patients With Advanced Melanoma
University of Pennsylvania
Phase 1 Completed
NCT05680454 2023-01-17
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 1 Completed
NCT05672966 2023-01-06
Phase I Clinical Trial of a Candidate HPV Vaccine
Wuhan BravoVax Co., Ltd.
Phase 1 Unknown
NCT01730118 2022-09-10
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03384316 2020-09-09
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00684294 2020-03-02
Auto TAG
Mary Crowley Medical Research Center
Phase 1 Terminated
NCT00988559 2018-07-09
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02745756 2017-08-30
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT00819806 2017-07-31
CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors
University of Pittsburgh
Phase 1 Completed
NCT01483274 2017-05-09
AML
University of Louisville
Phase 1 Withdrawn
NCT01829373 2013-04-11
Lung Cancer Vaccine Plus Oral Dietary Supplement
University of Kentucky
Phase 1 Completed